PBLS·Nasdaq·US
Parabilis
Parabilis is a clinical-stage biopharmaceutical company developing helical peptide therapeutics through its Helicon platform. Its lead programs target historically difficult protein interactions in oncology and other serious diseases, and the company also uses AI and data science within its discovery workflow.
Recent Activity
Updated Oct 31, 2026
–Parabilis Medicines presented updated Phase 1/2 data for zolucatetide in patients with desmoid tumors, which it described as showing compelling efficacy and a favorable safety and tolerability profile.
–Among response-evaluable patients receiving a starting dose of ≥450 mg, zolucatetide showed an objective response rate of 72.2% at the 32-week landmark.
–The company reported a disease control rate of 100% in the updated zolucatetide data.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.